New Ovarian Cancer Combo Shows Wider Promise

Verastem’s avutometinib/defactinib combination earned FDA approval for KRAS-mutated low-grade serous ovarian cancer, marking the first treatment specifically for this hard-to-treat subtype. Backed by preclinical and clinical data, the dual RAF/MEK and FAK inhibition strategy is now being explored in other cancers where standard MAPK-targeted therapies have fallen short.